講演・口頭発表等 - 加納　嘉人

1. Yoshihito Kano, Rika Noji, Takahiro Naito, Sadakatsu Ikeda, Hiroyuki Harada, Yasuo Hamamoto. Clinical Utility of Liquid Biopsy in HNSCC: Insights from the SHIZUKU-HN Study and C-CAT Data . 第22回日本臨床腫瘍学会学術集会 2025.03.06 神戸

2. Yoshihito Kano, Rika Noji, Kohki Tohyama, Takahiro Naito, Takuma Kugimoto, Takeshi Kuroshima, Hirofumi Tomioka, Yasuyuki Michi, Shun Fujiwara, Mitsukuni Suenaga, Shin Nakamura, Masahiko Miura, Hiroyuki Harada, Yasuo Hamamoto. Image Assessment and ctDNA Analysis in Evaluating Tumor Burden in Head and Neck Cancer Treated with ICIs. 第83回⽇本癌学会学術総会 2024.09.20

3. Yoshihito Kano. Impact of RAS Mutations on YAP-Driven Chemoresistance in Colorectal Cancer Organoids Cultured in Specific ECM Environments. The 8th JCA-AACR Special Joint Conference 2024.06.28

4. Yoshihito Kano. Prospective monitoring for immunotherapy by liquid biopsy and signal pathway alterations in head and neck cancers.. ASCO 2024 2024.06.01 Chicago

5. 松寺 翔太郎, 加納 嘉人, 岡本 健太郎, 鈴木 完, 小嶋 一幸, 三宅 智, 池田 貞勝. がんゲノム医療推進のためのがんプレシジョンメディシンフェローシッププログラム. 日本癌治療学会学術集会抄録集 2021.10.01

6. YOSHIHITO KANO, Teklab Gebregiworgis, Christopher Marshall, Mitsuhiko Ikura, Satoshi Miyake, Michael Ohh. KRAS Q61H mutation evades the regulation of tyrosyl phosphorylation and renders cancer cells resistant to SHP2 inhibitor. 第18回日本臨床腫瘍学会学術集会 2021.02.20

7. 加納 嘉人,野地 理夏, 山下 大和, 工藤 亮, 田崎 彰久, 大野 十央, 有泉 陽介, 平井 秀明, 富岡 寛文, 島本 裕彰, 道 泰之, 三浦 雅彦, 吉村 亮一, 朝蔭 孝宏, 原田 浩之, 岡本 隆一, 三宅 智, 池田 貞勝. Clinical utility of tumor-profiling multiplex gene panel testing in advanced head and neck cancer at TMDU. 第18回日本臨床腫瘍学会学術集会 2021.02.18

8. 加納嘉人、野地理夏、山下大和、工藤亮、大西威一郎、谷本幸介、宮冬樹、中川剛士、石川敏昭、植竹宏之、絹笠祐介、田邉稔、朝蔭孝宏、原田浩之、岡本隆一、三宅智、池田貞勝. Detection of RAS mutation in solid cancers using NGS-based genome profiling tests. 第18回日本臨床腫瘍学会学術集会 2021.02.18

9. Aoyagi Yasuko, Kano Yoshihito, Ban Daisuke, Tokunaga Masanori, Nakajima Yasuaki, Uetake Hiroyuki, Tanabe Minoru, Miyake Satoshi, Kinugasa Yusuke, Ikeda Sadakatsu. 消化器外科とゲノム医療の将来展望　進行性固形腫瘍患者における包括的ゲノムプロファイリングの臨床的有用性(Future perspectives of cancer genomic medicine in gastroenterological surgery　Clinical utility of multiple genomic testing in patients with advanced solid tumor). 日本消化器外科学会総会 2020.12.01

10. Yoshihito Kano, Teklab Gebregiworgis, Christopher B. Marshall, Mitsuhiko Ikura, Michael Ohh. Evasion of KRASQ61H regulation by tyrosine phosphorylation renders cancer cells resistant to SHP2 inhibitor. 第79回日本癌学会学術総会 2020.10.01 Hiroshima

11. 加納 嘉人, Gebregiworgis Teklab, Marshall Christopher, Ikura Mitsuhiko, Ohh Michael. ドライバー遺伝子異常陽性がん治療の新たな局面　KRASQ61H変異によるSHP2阻害剤耐性機構解析. 日本癌学会総会記事 2020.10.01

12. Yoshihito Kano, Teklab Gebregiworgis, Christopher Marshall,Mitsuhiko Ikura, Michael Ohh. Inhibition of SHP2 promotes the tyrosyl phosphorylation of KRAS and suppresses the pancreatic cancer growth. 第78回日本癌学会学術集会 2019.09.28 京都

13. 加納 嘉人, Gebregiworgis Teklab, Marshall Christopher, Ikura Mitsuhiko, Ohh Michael. チロシンリン酸化モデルに基づくKRAS変異膵癌に対する治療戦略(Inhibition of SHP2 promotes the tyrosyl phosphorylation of KRAS and suppresses the pancreatic cancer growth). 日本癌学会総会記事 2019.09.01

14. 加納嘉人,Teklab Gebregiworgis, Christopher Marshall, 伊倉 光彦, Michael Ohh. KRASチロシンリン酸化モデルに基づく膵癌新規分子機構と治療戦略. 第17回日本臨床腫瘍学会学術集会 2019.07.18

15. Yoshihito Kano, Teklab Gebregiworgis, Christopher B. Marshall, Nikolina Radulovich, Betty P.K. Poon, Zhong-Yin Zhang, Ming-Sound Tsao, Mitsuhiko Ikura and Michael Ohh. TYROSYL PHOSPHORYLATION OF KRAS DISRUPTS THE GTPASE CYCLE AND INHIBITS PANCREATIC CANCER CELL GROWTH.. DDW2018 2018.06.05

16. Teklab Gebregiworgis, Christopher B. Marshall, Yoshihito Kano, Nikolina Radulovich, Ming-Sound Tsao, Michael Ohh, Mitsuhiko Ikura. Altering the regulation of KRAS GTPase cycle via Src and SHP2 creates a potential therapeutic vulnerability for pancreatic cancer. . AACR 2018 2018.04.17

17. Kano Y. Tyrosyl phosphorylation of KRAS disrupts the GTPase cycle and inhibits pancreatic cancer cell growth. Pizza Talk of Department of Biochemistry 2018.03.21 Toronto(Canada)

18. Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon B P.K. , Zhang Z, Tsao M, Ikura M, Ohh M. Tyrosyl phosphorylation of KRAS disrupts the GTPase cycle and inhibits pancreatic cancer cell growth. . The Terry Fox Research Institute Ontario Node Research Symposium 2017.12.04 Toronto(Canada)

19. Kano Y, Poon P.K. B, Radulovich N, Zhang Z, Tsao M, Ohh M. Novel treatment strategy for pancreatic cancer by targeting SHP2-mediated dephosphorylation of KRAS oncoprotein. The 4th Canadian Cancer Research Conference 2017.11.06 Vancouver(Canada)

20. Kano Y. Poster Judge. 20th Annual LMP Graduate Research Conference 2017.04.13 Toronto(Canada)